Pacific Biosciences (PACB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 180,211 | 385,948 | 209,587 | 354,134 | 325,389 |
| Marketable Securities | 451,505 | 382,141 | 620,575 | 521,058 | 447,229 |
| Receivables | 36,615 | 30,486 | 24,034 | 29,589 | 18,786 |
| Inventories | 56,676 | 68,256 | 67,608 | 61,955 | 50,381 |
| TOTAL | $742,047 | $882,297 | $935,552 | $981,111 | $852,074 |
| Non-Current Assets | |||||
| PPE Net | 36,432 | 40,340 | 40,317 | 40,833 | 41,580 |
| Intangibles | 919,245 | 925,681 | 819,753 | 819,985 | 820,219 |
| Other Non-Current Assets | 48,289 | 50,036 | 52,009 | 54,488 | 53,213 |
| TOTAL | $1,003,966 | $1,016,057 | $912,079 | $915,306 | $915,012 |
| Total Assets | $1,746,013 | $1,898,354 | $1,847,631 | $1,896,417 | $1,767,086 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 15,062 | 16,106 | 16,512 | 17,390 | 12,028 |
| Accrued Expenses | 45,708 | 34,660 | 27,010 | 19,380 | 32,596 |
| Other current liabilities | 8,326 | 101,363 | 193,661 | 189,020 | 179,327 |
| TOTAL | $95,029 | $183,961 | $271,409 | $265,674 | $263,335 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 16,342 | 22,372 | 24,983 | 30,866 | 30,498 |
| Other Non-Current Liabilities | 944,150 | 945,597 | 929,231 | 936,777 | 939,053 |
| TOTAL | $949,680 | $950,650 | $934,223 | $938,626 | $940,847 |
| Total Liabilities | $1,044,709 | $1,134,611 | $1,205,632 | $1,204,300 | $1,204,182 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 267,952 | 267,444 | 250,558 | 249,891 | 247,079 |
| Common Shares | 268 | 258 | 250 | 250 | 227 |
| Retained earnings | -1,839,075 | -1,757,057 | -1,690,188 | -1,620,355 | -1,532,340 |
| Other shareholders' equity | 219 | -1,840 | -2,686 | -1,924 | -4,765 |
| TOTAL | $701,304 | $763,743 | $641,999 | $692,117 | $562,904 |
| Total Liabilities And Equity | $1,746,013 | $1,898,354 | $1,847,631 | $1,896,417 | $1,767,086 |